Both amyloid (Aβ) load and APOE4 allele are associated with neurodegenerative changes in Alzheimer’s disease (AD) prone regions and with risk for cognitive impairment.
Objective:
To evaluate the unique and independent contribution of APOE4 allele status (E4+∖E4–), Aβ status (Amy+∖Amy–), and combined APOE4 and Aβ status on regional cortical thickness (CoTh) and cognition among participants diagnosed as cognitively normal (CN, n = 251), early mild cognitive impairment (EMCI, n = 207), late mild cognitive impairment (LMCI, n = 196), and mild AD (n = 162) from the ADNI.
Methods:
A series of two-way ANCOVAs with post-hoc Tukey HSD tests, controlling independently for Aβ and APOE4 status and age were examined.
Results:
Among LMCI and AD participants, cortical thinning was widespread in association with Amy+ status, whereas in association with E4+ status only in the inferior temporal and medial orbito-frontal regions. Among CN and EMCI participants, E4+ status, but not Amy+ status, was independently associated with increased CoTh, especially in limbic regions [e.g., in the entorhinal cortex, CoTh was 0.123 mm greater (p = 0.002) among E4+ than E4–participants]. Among CN and EMCI, both E4+ and Amy+ status were independently associated with cognitive impairment, which was greatest among those with combined E4 + and Amy+ status.
Conclusion:
Decreased CoTh is independently associated with Amy+ status in many brain regions, but with E4+ status in very restricted number of brain regions. Among CN and EMCI participants, E4 + status is associated with increased CoTh, in medial and inferior temporal regions, although cognitive impairment at this state is independently associated with Amy+ and E4 + status. These findings imply a unique pathophysiological mechanism for E4 + status in AD and its progression.
SelkoeDJ (1991) The molecular pathology of Alzheimer’s disease. Neuron6, 487–498.
2.
HymanBT, PhelpsCH, BeachTG, BigioEH, CairnsNJ, CarrilloMC, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, ThiesB, TrojanowskiJQ, VintersHV, MontineTJ (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement8, 1–13.
3.
MurphyKR, LandauSM, ChoudhuryKR, HostageCA, ShpanskayaKS, SairHI, PetrellaJR, WongTZ, DoraiswamyPM, Alzheimer’s Disease Neuroimaging Initiative (2013) Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. Neuroimage78, 474–480.
4.
DrzezgaA, GrimmerT, HenriksenG, MuhlauM, PerneczkyR, MiedererI, PrausC, SorgC, WohlschlagerA, RiemenschneiderM, WesterHJ, FoerstlH, SchwaigerM, KurzA (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology72, 1487–1494.
5.
FleisherAS, ChenK, LiuX, AyutyanontN, RoontivaA, ThiyyaguraP, ProtasH, JoshiAD, SabbaghM, SadowskyCH, SperlingRA, ClarkCM, MintunMA, PontecorvoMJ, ColemanRE, DoraiswamyPM, JohnsonKA, CarpenterAP, SkovronskyDM, ReimanEM (2013) Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging34, 1–12.
6.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
7.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCR, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
JackCRJr, WisteHJ, WeigandSD, KnopmanDS, VemuriP, MielkeMM, LoweV, SenjemML, GunterJL, MachuldaMM, GreggBE, PankratzVS, RoccaWA, PetersenRC (2015) Age, sex, and APOE epsilon4 effects on memory, brain structure, and beta-amyloid across the adult life span. JAMA Neurol72, 511–519.
10.
VemuriP, WisteHJ, WeigandSD, KnopmanDS, ShawLM, TrojanowskiJQ, AisenPS, WeinerM, PetersenRC, JackCRJr, Alzheimer’s Disease Neuroimaging Initiative (2010) Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol67, 308–316.
11.
CaselliRJ, DueckAC, OsborneD, SabbaghMN, ConnorDJ, AhernGL, BaxterLC, RapcsakSZ, ShiJ, WoodruffBK, LockeDE, SnyderCH, AlexanderGE, RademakersR, ReimanEM (2009) Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med361, 255–263.
12.
MorrisJC (1993) The Clinical Dementia Rating (CDR) - current version and scoring rules. Neurology43, 2412–2414.
13.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
14.
ReyA (1964) L’ examen clinique en psychologie, Presses universitaires de France, Paris.
15.
DesikanRS, SegonneF, FischlB, QuinnBT, DickersonBC, BlackerD, BucknerRL, DaleAM, MaguireRP, HymanBT, AlbertMS, KillianyRJ (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage31, 968–980.
16.
DickersonBC, BakkourA, SalatDH, FeczkoE, PachecoJ, GreveDN, GrodsteinF, WrightCI, BlackerD, RosasHD, SperlingRA, AtriA, GrowdonJH, HymanBT, MorrisJC, FischlB, BucknerRL (2009) The cortical signature of Alzheimer’s disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex19, 497–510.
17.
BeckerJA, HeddenT, CarmasinJ, MayeJ, RentzDM, PutchaD, FischlB, GreveDN, MarshallGA, SallowayS, MarksD, BucknerRL, SperlingRA, JohnsonKA (2011) Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol69, 1032–1042.
JoshiAD, PontecorvoMJ, ClarkCM, CarpenterAP, JenningsDL, SadowskyCH, AdlerLP, KovnatKD, SeibylJP, AroraA, SahaK, BurnsJD, LowreyMJ, MintunMA, SkovronskyDM, Florbetapir F 18 Study Investigators (2012) Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects. J Nucl Med53, 378–384.
20.
LoewensteinDA, CurielRE, GreigMT, BauerRM, RosadoM, BowersD, WicklundM, CroccoE, PontecorvoM, JoshiAD, RodriguezR, BarkerWW, HidalgoJ, DuaraR (2016) A novel cognitive stress test for the detection of preclinical Alzheimer disease: Discriminative properties and relation to amyloid load. Am J Geriatr Psychiatry24, 804–813.
21.
R Core Team (2017) R Foundation for Statistical Computing, Vienna, Austria.
22.
TrojanowskiJQ, VandeersticheleH, KoreckaM, ClarkCM, AisenPS, PetersenRC, BlennowK, SoaresH, SimonA, LewczukP, DeanR, SiemersE, PotterWZ, WeinerMW, JackCR, JagustW, TogaAW, LeeVMY, ShawLM, Alzheimer’s Disease Neuroimaging Initiative (2010) Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. Alzheimers Dement6, 230–238.
23.
FleisherAS, ChenK, LiuX, RoontivaA, ThiyyaguraP, AyutyanontN, JoshiAD, ClarkCM, MintunMA, PontecorvoMJ, DoraiswamyPM, JohnsonKA, SkovronskyDM, ReimanEM (2011) Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol68, 1404–1411.
24.
EllisKA, LimYY, HarringtonK, AmesD, BushAI, DarbyD, MartinsRN, MastersCL, RoweCC, SavageG, SzoekeC, VillemagneVL, MaruffP, AIBL Research Group (2013) Decline in cognitive function over 18 months in healthy older adults with high amyloid-beta. J Alzheimers Dis34, 861–871.
25.
MielkeMM, MachuldaMM, HagenCE, ChristiansonTJ, RobertsRO, KnopmanDS, VemuriP, LoweVJ, KremersWK, JackCR, PetersenRC (2016) Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort. Alzheimers Dement12, 281–291.
26.
LimYY, EllisKA, AmesD, DarbyD, HarringtonK, MartinsRN, MastersCL, RoweC, SavageG, SzoekeC, VillemagneVL, MaruffP, AIBL Research Group (2013) Abeta amyloid, cognition, and APOE genotype in healthy older adults. Alzheimers Dement9, 538–545.
27.
WhitwellJL, TosakulwongN, WeigandSD, SenjemML, LoweVJ, GunterJL, BoeveBF, KnopmanDS, DickersonBC, PetersenRC, JackCR (2013) Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?Neuroimage Clin2, 249–257.
DaX, ToledoJB, ZeeJ, WolkDA, XieSX, OuY, ShacklettA, ParmpiP, ShawL, TrojanowskiJQ, DavatzikosC, Alzheimer’s Neuroimaging Initiative (2014) , Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin4, 164–173.
30.
ChetelatG, La JoieR, VillainN, PerrotinA, de La SayetteV, EustacheF, VandenbergheR (2013) Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease. Neuroimage Clin2, 356–365.
31.
ListaS, GaraciFG, EwersM, TeipelS, ZetterbergH, BlennowK, HampelH (2014) CSF Abeta1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimers Dement10, 381–392.
32.
DuaraR, LoewensteinDA, ShenQ, BarkerW, PotterE, VaronD, HeurlinK, VandenbergheR, BuckleyC (2013) Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement9, 295–301.
33.
GrotheMJ, TeipelSJ, Alzheimer’s Disease Neuroimaging Initiative (2016) Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer’s disease correspond to dissociable functional brain networks. Hum Brain Mapp37, 35–53.
LiuY, PaajanenT, WestmanE, WahlundLO, SimmonsA, TunnardC, SobowT, ProitsiP, PowellJ, MecocciP, TsolakiM, VellasB, MuehlboeckS, EvansA, SpengerC, LovestoneS, SoininenH, AddNeuroMed Consortium (2010) Effect of APOE epsilon4 allele on cortical thicknesses and volumes: The AddNeuroMed study. J Alzheimers Dis21, 947–966.
36.
LemaitreH, CrivelloF, DufouilC, GrassiotB, TzourioC, AlperovitchA, MazoyerB (2005) No epsilon(4) gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. Neuroimage24, 1205–1213.
37.
MaturaS, PrvulovicD, JurcoaneA, HartmannD, MillerJ, ScheibeM, O’DwyerL, Oertel-KnochelV, KnochelC, ReinkeB, KarakayaT, FusserF, PantelJ (2014) Differential effects of the ApoE4 genotype on brain structure and function. Neuroimage89, 81–91.
38.
PievaniM, GalluzziS, ThompsonPM, RasserPE, BonettiM, FrisoniGB (2011) APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer’s disease. Neuroimage55, 909–919.
39.
FouquetM, BessonFL, GonneaudJ, La JoieR, ChetelatG (2014) Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan. Neuropsychol Rev24, 290–299.
40.
ChetelatG, FouquetM (2013) Neuroimaging biomarkers for Alzheimer’s disease in asymptomatic APOE4 carriers. Rev Neurol (Paris)169, 729–736.
41.
FilippiniN, RaoA, WettenS, GibsonRA, BorrieM, GuzmanD, KerteszA, Loy-EnglishI, WilliamsJ, NicholsT, WhitcherB, MatthewsPM (2009) Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer’s disease. Neuroimage44, 724–728.
42.
HeiseV, FilippiniN, TrachtenbergAJ, SuriS, EbmeierKP, MackayCE (2014) Apolipoprotein E genotype, gender and age modulate connectivity of the hippocampus in healthy adults. Neuroimage98, 23–30.
43.
ChangL, AndresM, SadinoJ, JiangCS, NakamaH, MillerE, ErnstT (2011) Impact of apolipoprotein E epsilon4 and HIV on cognition and brain atrophy: Antagonistic pleiotropy and premature brain aging. Neuroimage58, 1017–1027.
44.
PettigrewC, SoldanA, ZhuY, WangMC, MoghekarA, BrownT, MillerM, AlbertM, TeamBR (2016) Cortical thickness in relation to clinical symptom onset in preclinical AD. Neuroimage Clin12, 116–122.
45.
LinH, BhatiaR, LalR (2001) Amyloid beta protein forms ion channels: Implications for Alzheimer’s disease pathophysiology. FASEB J15, 2433–2444.
46.
Rosales-CorralS, TanDX, ReiterRJ, Valdivia-VelazquezM, Acosta-MartinezJP, OrtizGG (2004) Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-beta onto the hippocampus in vivo. J Neuroimmunol150, 20–28.
47.
ButterfieldDA, ReedT, NewmanSF, SultanaR (2007) Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer’s disease and mild cognitive impairment. Free Radic Biol Med43, 658–677.
LiC, LoewensteinDA, DuaraR, CabrerizoM, BarkerW, AdjouadiM (2017) Associations between regional amyloid load, cortical thickness, APOE genotype and cognition in ADNIGO/ADNI2 participants. In Human Amyloid Imaging, Miami, FL, pp. 221–224.
51.
NhoK, RisacherSL, CranePK, DeCarliC, GlymourMM, HabeckC, KimS, LeeGJ, MorminoE, MukherjeeS, ShenL, WestJD, SaykinAJ, Alzheimer’s Disease Neuroimaging Initiative (2012) Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer’s disease. Brain Imaging Behav6, 551–567.
52.
ChenKW, LangbaumJBS, FleisherAS, AyutyanontN, ReschkeC, LeeW, LiuXF, BandyD, AlexanderGE, ThompsonPM, FosterNL, HarveyDJ, de LeonMJ, KoeppeRA, JagustWJ, WeinerMW, ReimanEM, Alzheimer’s Disease Neuroimaging Initiative (2010) Twelve-month metabolic declines in probable Alzheimer’s disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer’s Disease Neuroimaging Initiative. Neuroimage51, 654–664.
53.
WolfAB, VallaJ, BuG, KimJ, LaDuMJ, ReimanEM, CaselliRJ (2013) Apolipoprotein E as a beta-amyloid-independent factor in Alzheimer’s disease. Alzheimers Res Ther5, 38.
54.
DickersonBC, SalatDH, GreveDN, ChuaEF, Rand-GiovannettiE, RentzDM, BertramL, MullinK, TanziRE, BlackerD, AlbertMS, SperlingRA (2005) Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology65, 404–411.
55.
MahleyRW, WeisgraberKH, HuangY (2006) Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci U S A103, 5644–5651.
56.
RisacherSL, KimS, ShenL, NhoK, ForoudT, GreenRC, PetersenRC, JackCR, AisenPS, KoeppeRA, JagustWJ, ShawLM, TrojanowskiJQ, WeinerMW, SaykinAJ, Alzheimer’s Disease Neuroimaging Initiative (ADNI) (2013) The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci5, 11.
57.
EspesethT, WestlyeLT, WalhovdKB, FjellAM, EndestadT, RootweltH, ReinvangI (2012) Apolipoprotein E epsilon4-related thickening of the cerebral cortex modulates selective attention. Neurobiol Aging33, 304–322.
